Investigating kidney damage from immune checkpoint inhibitors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to explore the nephrotoxicity associated with immune checkpoint inhibitors (ICIs) used in cancer treatment. It focuses on identifying early and predisposition biomarkers for kidney injury in patients undergoing immunotherapy or combination therapies. By understanding the subclinical renal lesions that may arise, the study seeks to enhance patient management through preventive and early diagnostic strategies. The research will involve patients who are about to start immunotherapy, assessing their kidney function and potential risks.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients waiting for immunotherapy or combination immunotherapy / platinum compounds

Exclusion Criteria:

* Patients who are terminally ill
* Patients who do not wish to sign the informed consent

Where it's running

• Servicio de Oncología del CAUSA
  Salamanca, Spain Recruiting
• Servicio de oncología del Hospital Universitario de Valladolid
  Valladolid, Spain Recruiting

Study contacts

• Principal investigator: Ana Isabel Morales Martín, PhD — University of Salamanca
• Study coordinator: Ana Isabel Morales Martín, PhD
• Email: amorales@usal.es
• Phone: +34923294400

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• See if extra caffeine helps preterm babies with kidney oxygen problems

  This study tests whether giving additional caffeine to very premature babies with low kidney oxygen levels can improve kidney health without harming the brain.

  Recruiting Phase 2 University of Wisconsin, Madison · Madison, Wisconsin · NCT07262060

• Stopping heart failure medications in cancer survivors with heart dysfunction

  This study is testing if cancer survivors with improved heart function can safely stop taking their heart failure medications to see if it reduces their pill burden and side effects.

  Recruiting at 8 sites Phase 4 University Health Network, Toronto · Los Angeles, California and 13 other locations · NCT06183437

• Effects of a medication on blood vessel function and organ injury in heart surgery patients

  This study tests if a medication called vericiguat can improve blood vessel function and reduce kidney and brain injury in patients having heart surgery.

  Recruiting Phase 4 Vanderbilt University Medical Center · Nashville, Tennessee · NCT05812755

• Research on heart and kidney disease interactions

  This study looks at how heart and kidney problems affect each other to find better treatment options for people with cardiorenal syndrome.

  Recruiting Nanjing First Hospital, Nanjing Medical University · Nanjing · NCT05397392

• Study on complications and long-term outcomes after high-risk surgeries

  This study is trying to see how well we can predict and identify complications in patients having high-risk surgeries by monitoring them closely after their operations.

  Recruiting UMC Utrecht · Utrecht · NCT05331118

• Comparing IV and oral hydration to prevent kidney injury after CT scans in severe kidney disease patients

  This study is testing whether drinking fluids can be just as good as getting IV fluids to help prevent kidney injury in patients with severe kidney disease who are having a CT scan.

  Recruiting Odense University Hospital · Odense C, Fyn · NCT05283512

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.